Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease
NCT00138840
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
282
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn's Disease
Interventions
DRUG:
STA-5326 mesylate
Sponsor
Synta Pharmaceuticals Corp.